Breaking News Instant updates and real-time market news.

MRK

Merck

$63.78

-0.68 (-1.05%)

16:46
10/11/17
10/11
16:46
10/11/17
16:46

Merck says will not submit applications for regulatory approval for anacetrapib

Merck announced that the company will not submit applications for regulatory approval for anacetrapib, Merck's investigational cholesteryl ester transfer protein inhibitor. The decision follows a thorough review of the clinical profile of anacetrapib, including discussions with external experts. "We are deeply grateful to the researchers and patients who participated in the anacetrapib clinical development program, and in particular the REVEAL outcomes study. Unfortunately, after comprehensive evaluation, we have concluded that the clinical profile for anacetrapib does not support regulatory filings," said Roger Perlmutter, M.D., Ph.D., president, Merck Research Laboratories. "During the past half-century, Merck has made numerous, important contributions to the treatment of cardiovascular disease. Our work in cardiovascular research continues."

  • 17

    Oct

  • 17

    Oct

  • 23

    Oct

  • 27

    Oct

  • 06

    Nov

  • 08

    Nov

  • 30

    Nov

  • 02

    Feb

MRK Merck
$63.78

-0.68 (-1.05%)

08/23/17
RAJA
08/23/17
NO CHANGE
Target $36
RAJA
Strong Buy
Paratek takeover speculation 'seems plausible,' says Raymond James
After Bloomberg reported that Paratek Pharmaceuticals (PRTK) is exploring its strategic options, including a possible sale, after receiving takeover interest, Raymond James analyst Laura Chico said she sees omadacycline as a promising asset and sees a takeout as "certainly one plausible outcome." While its "probably premature to think about a takeout price," Chico said that a possible price could arguably fall in the high-$40 to low-$50 range, adding that Merck (MRK), Pfizer (PFE) and Allergan (AGN) would all be potential buyers. She keeps a Strong Buy rating and $36 price target on Paratek shares.
09/11/17
STFL
09/11/17
NO CHANGE
Target $29
STFL
Buy
NewLink Genetics price target raised to $29 from $14 at Stifel
Stifel analyst Stephen Willey believes recently-updated melanoma data from both NewLink Genetics' (NLNK) phase 2 indoximod program and Incyte (INCY) and Merck's (MRK) ESMO presentation confirm IDO inhibitors are more-than-likely synergizing with PD-1 inhibition, adding that NewLink's drug appears to yield "slightly-better efficacy" in "slightly-healthier" patients. He increased his price target on NewLink to $29 from $14 to reflect favorable risk adjustments and higher melanoma sales estimates and keeps a Buy rating on the stock.
09/11/17
BMOC
09/11/17
NO CHANGE
BMOC
Incyte trial result 'assures commercial success,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says the results of a trial of Incyte's (INCY) epacadostat, its selective IDO1 enzyme inhibitor, in combination with Merck's (MRK) Keytruda, in patients with advanced melanoma eliminates the risk of an upcoming Phase 3 trial of epacadostat and "assures its commercial success." The analyst adds, however, that "the bar continues to be raised for IO combinations," which may make it difficult for Incyte's stock to rise in the near-term. The analyst trimmed his price target on the shares to $163 from $172 to reflect the company's capital raise. But he keeps an Outperform rating on the stock.
09/18/17
JEFF
09/18/17
NO CHANGE
JEFF
AbbVie remains top global Pharma pick at Jefferies
Jefferies analyst Jeffrey Holford says AbbVie (ABBV) remains his top global pick in Pharmaceuticals, followed by Bayer (BAYRY). In the U.S., the analyst lists Zoetis (ZTS), Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) as his top picks behind AbbVie. Merck (MRK) and Novo Nordisk (NVO) are the analyst's least preferred stocks. Holford cut his price target for Underperform-rated Merck to $52 from $55 and raised his price target for Buy-rated Zoetis to $77 from $74.

TODAY'S FREE FLY STORIES

WRI

Weingarten Realty

$27.15

-0.55 (-1.99%)

03:37
02/22/18
02/22
03:37
02/22/18
03:37
Downgrade
Weingarten Realty rating change  »

Weingarten Realty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

MNTA

Momenta

$16.35

0.4 (2.51%)

03:36
02/22/18
02/22
03:36
02/22/18
03:36
Upgrade
Momenta rating change  »

Momenta upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HOC

Holly

03:35
02/22/18
02/22
03:35
02/22/18
03:35
Upgrade
Holly rating change  »

Holly upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLVS

Clovis

$54.93

1.22 (2.27%)

03:34
02/22/18
02/22
03:34
02/22/18
03:34
Upgrade
Clovis rating change  »

Clovis upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

HST

Host Hotels

$19.22

-0.29 (-1.49%)

03:34
02/22/18
02/22
03:34
02/22/18
03:34
Upgrade
Host Hotels rating change  »

Host Hotels upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

SLCA

U.S. Silica

$25.15

-5.6 (-18.21%)

03:33
02/22/18
02/22
03:33
02/22/18
03:33
Downgrade
U.S. Silica rating change  »

U.S. Silica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

JELD

Jeld-Wen

$34.50

-3.14 (-8.34%)

03:33
02/22/18
02/22
03:33
02/22/18
03:33
Downgrade
Jeld-Wen rating change  »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

TEO

Telecom Argentina

$34.09

-0.19 (-0.55%)

03:32
02/22/18
02/22
03:32
02/22/18
03:32
Downgrade
Telecom Argentina rating change  »

Telecom Argentina…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

03:30
02/22/18
02/22
03:30
02/22/18
03:30
General news
FX Action: USD-CAD clocked a two-month high »

FX Action: USD-CAD…

JELD

Jeld-Wen

$34.50

-3.14 (-8.34%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Jeld-Wen rating change  »

Jeld-Wen downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Mar

ALKS

Alkermes

$63.19

-1.56 (-2.41%)

03:27
02/22/18
02/22
03:27
02/22/18
03:27
Downgrade
Alkermes rating change  »

Alkermes downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSA

MSA Safety

$80.25

3.79 (4.96%)

03:25
02/22/18
02/22
03:25
02/22/18
03:25
Upgrade
MSA Safety rating change  »

MSA Safety upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Mar

02:50
02/22/18
02/22
02:50
02/22/18
02:50
General news
FX Update: The dollar has continued to mostly trade firmer »

FX Update: The dollar…

02:15
02/22/18
02/22
02:15
02/22/18
02:15
General news
Asian Market Summary: »

Asian Market Summary:…

00:00
02/22/18
02/22
00:00
02/22/18
00:00
General news
Breaking General news story  »

Federal Reserve Vice…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

, HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

20:25
02/21/18
02/21
20:25
02/21/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

NEM

Newmont Mining

$38.16

-0.23 (-0.60%)

HRL

Hormel Foods

$32.68

-1.12 (-3.31%)

APA

Apache

$37.20

-1.1 (-2.87%)

LDOS

Leidos

$65.21

-1.02 (-1.54%)

W

Wayfair

$95.69

-0.61 (-0.63%)

OA

Orbital ATK

$131.80

-0.02 (-0.02%)

TREE

LendingTree

$371.25

-7.8 (-2.06%)

SFM

Sprouts Farmers Market

$26.12

0.12 (0.46%)

TPX

Tempur Sealy

$54.97

1.17 (2.17%)

SAFM

Sanderson Farms

$128.00

-3.44 (-2.62%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 21

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 25

    Feb

  • 28

    Feb

  • 07

    Mar

  • 08

    Mar

  • 20

    Mar

  • 29

    Mar

AIMT

Aimmune

$32.21

-2.75 (-7.87%)

20:04
02/21/18
02/21
20:04
02/21/18
20:04
Syndicate
Aimmune 5.5M share Secondary priced at $32.00 »

BofA/Merrill, Cantor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 11

    Mar

  • 22

    Feb

20:00
02/21/18
02/21
20:00
02/21/18
20:00
General news
Breaking General news story  »

Minneapolis Federal…

NUAN

Nuance

$16.28

-0.28 (-1.69%)

19:10
02/21/18
02/21
19:10
02/21/18
19:10
Periodicals
Nuance discontinues Swype feature development, Verge reports »

Nuance has ceased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

SSNLF

Samsung

, QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

19:04
02/21/18
02/21
19:04
02/21/18
19:04
Hot Stocks
Samsung, Qualcomm expand foundry cooperation on EUV process technology »

Samsung Electronics…

SSNLF

Samsung

QCOM

Qualcomm

$63.40

-0.59 (-0.92%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 06

    Mar

CATY

Cathay General

$42.84

0.43 (1.01%)

18:59
02/21/18
02/21
18:59
02/21/18
18:59
Hot Stocks
Cathay General executive chairman Cheng sells 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUN

Sunoco

$30.00

-0.08 (-0.27%)

18:42
02/21/18
02/21
18:42
02/21/18
18:42
Earnings
Sunoco reports Q4 EPS $2.01, may not compare to consensus 35c »

Reports Q4 revenue $3B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

USFD

US Foods

$32.29

0.33 (1.03%)

18:39
02/21/18
02/21
18:39
02/21/18
18:39
Hot Stocks
US Foods director Lederer sells 98,702 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:38
02/21/18
02/21
18:38
02/21/18
18:38
Earnings
Volaris reports Q4 28c, consensus 20c »

Reports Q4 revenue $336M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLRS

Volaris

$9.14

0.12 (1.33%)

18:34
02/21/18
02/21
18:34
02/21/18
18:34
Earnings
Breaking Earnings news story on Volaris »

Volaris reports Q4 net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.